Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Understanding how a clinical-stage biotech finances multi-year Alzheimer’s trials is tough. Acumen Pharmaceuticals’ 10-K details R&D burn rates, dilution risk and the science behind sabirnetug, yet the narrative spans hundreds of pages filled with immunology jargon. Quarterly 10-Q updates land while insiders file Form 4s minutes after the market closes. Investors who need those data points fast often ask, “Where can I find Acumen Pharmaceuticals’ quarterly earnings report 10-Q filing?” or “How do I monitor Acumen Pharmaceuticals insider trading Form 4 transactions in real time?”
Stock Titan’s AI reads every line the moment a document hits EDGAR. Our platform turns an intimidating 8-K about a Phase 2 interim readout into plain-English bullet points, flags cash-runway shifts inside the MD&A, and surfaces Acumen Pharmaceuticals executive stock transactions Form 4. Whether you want “Acumen Pharmaceuticals annual report 10-K simplified,” “Acumen Pharmaceuticals proxy statement executive compensation,” or “Acumen Pharmaceuticals 8-K material events explained,” we’ve already summarized it.
All SEC documents appear in one feed with:
- AI-powered summaries for quick context
- Real-time alerts on Acumen Pharmaceuticals Form 4 insider transactions
- Side-by-side Acumen Pharmaceuticals earnings report filing analysis for each 10-Q
That means you can:
- Track cash usage against projected trial milestones
- Compare R&D spend quarter over quarter
- Spot insider buying before material announcements
If you have ever searched for “understanding Acumen Pharmaceuticals SEC documents with AI” or needed “Acumen Pharmaceuticals SEC filings explained simply” before a decision, this page answers it. Complex biotech disclosures are distilled into what matters: the progress of sabirnetug, funding runway, and the timing of clinical catalysts. No scrolling, no medical dictionaries—just the essentials, updated the second Acumen hits “submit.”
Neuronetics, Inc. (Nasdaq: STIM) filed an 8-K on 15 July 2025 announcing a key leadership change. The Board appointed Steven Pfanstiel (age 52) as Executive Vice President, Chief Financial Officer and Treasurer, effective immediately.
Professional background: Pfanstiel most recently held CFO and COO posts at Marinus Pharmaceuticals (2021-2025) and previously served in senior finance roles at LifeScan, OptiNose and Johnson & Johnson subsidiaries. His academic credentials include a B.A. in Physics, an M.S. in Environmental Systems Engineering and an MBA.
Compensation package:
- Base salary: $480,000
- Target annual bonus: 50 % of base
- Equity grant: 400,000 restricted stock units—half vest over 1-3 years and half over 2-4 years, contingent on continued service
- Severance (termination without cause or for good reason): 12 months base salary, prorated target bonus and continued health coverage
Mr. Pfanstiel signed the Company’s standard indemnification, restrictive-covenant and invention-assignment agreements.
Regulation FD disclosure: The accompanying press release (Exhibit 99.1) both announces the appointment and reaffirms previously issued Q2 and FY-2025 financial guidance. No new numerical guidance was provided.
Investor takeaway: The hire adds a seasoned life-sciences finance executive ahead of anticipated growth initiatives, while the reiterated outlook signals management confidence in near-term performance.
FAQ
What is the current stock price of Acumen Pharmaceuticals (ABOS)?
What is the market cap of Acumen Pharmaceuticals (ABOS)?
What therapeutic area does Acumen Pharmaceuticals focus on?
What is sabirnetug (ACU193)?
How does Acumen Pharmaceuticals differentiate itself in the Alzheimer’s treatment space?
What are the key components of Acumen’s research approach?
What stage of clinical development is Acumen’s drug candidate?
How do Acumen’s strategic collaborations support its operations?
